Amgen, based in Thousand Oaks, CA, announced that the U.S. FDA has approved the supplemental New Drug Application (sNDA) of Kyprolis®(carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.  Kyprolis is the only approved therapy for relapsed multiple myeloma with proven efficacy as a single agent, doublet and triplet combination that is offered in a variety of doses to meet individual patient needs.  Multiple myeloma is an incurable blood cancer, characterized by a recurring pattern of remission and relapse.  It is a rare and very aggressive disease that accounts for approximately one percent of all cancers.  In the U.S., there are nearly 90,000 people living with, or in remission from, multiple myeloma.

 

Source:

http://www.amgen.com/media/news-releases/2016/01/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/